{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"41","value":"62.55"},{"groupId":"OG001","spread":"29","value":"87.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"LDAC Cycle 1/Day 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"76","value":"65.56"},{"groupId":"OG001","spread":"26","value":"134.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"LDAC Cycle 1/Day 10"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36","value":"2036"},{"groupId":"OG001","spread":"29","value":"3050"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Ara-U Cycle 1/Day 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"43","value":"2283"},{"groupId":"OG001","spread":"29","value":"3528"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Ara-U Cycle 1/Day 10"}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Ara-U is the major metabolite of cytarabine. LDAC (low dose cytarabine) is rapidly degraded to the stable metabolite Ara-U. Area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration (AUClast) levels of both LDAC and Ara-U were reported.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received oral doses of glasdegib (PF-04449913) tablets 100 milligram (mg) starting on Day 3 of Cycle 1 for pharmacokinetic (PK) assessment purposes and thereafter once daily (QD) and continuously for 28-day cycles (starting on Day 1 for all other cycles). LDAC was given at a dose of 20 mg subcutaneously twice daily (BID) on Days 1-10 of the 28-day cycles.","id":"OG000","title":"Phase 1B: Glasdegib 100 mg + LDAC"},{"description":"Participants received oral doses of glasdegib tablets 200 mg starting on Day 3 of Cycle 1 for PK assessment purposes and thereafter QD and continuously for 28-day cycles (starting on Day 1 for all other cycles). LDAC was given at a dose of 20 mg subcutaneously BID on Days 1-10 of the 28-day cycles. In March 2013, all active participants receiving glasdegib 200 mg were required to reduce dose to 100 mg. Participants who had glasdegib dose reduction were reported as the starting glasdegib dose level received. Two (2) participants in this cohort had dose reduction to 100 mg starting from Cycle 2/Day 1 and Cycle 2/Day 16, respectively.","id":"OG001","title":"Phase 1B: Glasdegib 200 mg + LDAC"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK parameter analysis set: all treated participants who had at least 1 of the PK parameters of interest for any of the study drugs.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.25, 0.5, 1, 2, 4 and 6 hours post-dose on Cycle 1/Day 2 and Cycle 1/Day 10","title":"Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of LDAC and Ara-U in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 2 and Cycle 1/Day 10","type":"SECONDARY","unitOfMeasure":"ng*hr/mL"}